

PiFlufoLastat approved as diagnostic tool for adults with prostate cancer

The Medicines and Healthcare products Regulatory Agency (MHRA) has today (6 March 2024) approved the medicine piFlufoLastat (18F) (Pylclari) as a diagnostic tool for people with suspected or known prostate cancer.